openpr.com
Cure8 news brief
Why This Matters
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability, costs, or prescribing trends.
It also names the companies and drugs likely to shape the Crohn's disease treatment landscape through 2034.
Who Should Pay Attention
People with Crohn's disease, caregivers, clinicians prescribing biologics, patients on or considering biologic/JAK/S1P therapies, and researchers or industry watchers.
Study Snapshot
Story typePress release
Evidence typeMarket or Business News
Source depthFull source text
What To Know
The piece is a commercial market-report summary rather than original clinical research. It highlights approved drugs and several investigational medicines (for example, vedolizumab, ustekinumab, mirikizumab, guselkumab, etrasimod, ozanimod) and mentions recent trial updates and a biosimilar approval.
The report also outlines disease burden, common symptoms, and possible complications. If you read the original DelveInsight report linked in the article, expect more detailed market forecasts, company profiles, and epidemiology data; this openPR post mainly republishes key findings and product names. This is not medical advice.
For treatment decisions or questions about a specific drug, talk with your gastroenterology team.
Keep In Mind
This is a business/market report summary that aggregates public trial announcements, regulatory outcomes, and company information. It does not present new clinical data or clinical guidance. Mentioned trial results and approvals are summarized; consult the original clinical publications or regulatory notices for full details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationopenpr.com
Indexed viaGoogle News
Source typePress release
PublishedFeb 19, 2025, 2:16 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
Crohn's Disease Market Report 2034: Epidemiology Data, - openPR.com
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...